Low‐Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non‐Diabetic Japanese Adults
Main finding · BMI < 25 kg/m² or > 15% body weight reductionResult — go to the resultHazard ratio 0.93 95% CI 0.58–1.49Authors' conclusion
In non-diabetic Japanese adults with obesity, 2.5 and 5 mg tirzepatide combined with lifestyle modification yielded similar weight loss at 6 months, with better tolerability at the lower dose.
Study context
- Population
- Non-diabetic Japanese adults (18–65 years) with BMI ≥ 30 kg/m² or ≥ 27 kg/m² with comorbidities; dose chosen by shared decision-making; all received dietary and exercise counsellinganalysed
- Participants
- 112 adults
- Exposure
- Tirzepatide 2.5 mg vs 5 mg weekly, with lifestyle intervention
- 2.5 mgn = 58reference
- 5 mgn = 54
- Outcome
- Proportion achieving BMI < 25 kg/m² or > 15% body weight reduction
- Follow-up
- 6 months
Methodological detailsmulticentre, non-randomised
- Multicentre
- Non-randomised
Main finding
BMI < 25 kg/m² or > 15% body weight reduction
Hazard ratio
0.93
95% CI 0.58–1.49
P = 0.772
By group
2.5 mgvs 5 mg
HR 0.93 (95% CI 0.58–1.49); P = 0.772
As reported in the abstract
Observational data: associations, not effects.
Further findings
Mean, %
| Outcome | 2.5 mg | 5 mg | P value |
|---|---|---|---|
| Percent weight loss · 6 months | −15.3 | −16.1 | P = 0.563 |
Percent weight loss · 6 months
- Similar reductions in BMI, skeletal muscle mass, and bone mass
Lifestyle adherence
- Adherence to dietary therapy, both groups
- 96.4%
- Exercise adherence
- 37.5%
Safety
Adverse events, primarily gastrointestinal symptoms
Original publication
Low‐Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non‐Diabetic Japanese Adults. Diabetes Obes Metab. Published 28 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →